Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Globe Newswire•04/11/2026•09:00 ET
0
Key Highlights
- ➤Risto-cel BEACON data selected for ASH’s official press program and oral presentation
- ➤Patient-reported outcomes show improvements in physical function, pain, fatigue and well-being
- ➤U.S. BLA submission for risto-cel expected as early as year-end 2026
Expert Statements
Amy Simon, Chief Medical Officer of Beam Therapeutics
“With more patients and longer follow-up, the updated BEACON data continue to demonstrate risto-cel’s differentiated clinical and manufacturing profile and its potential to provide a meaningful treatment option for patients living with sickle cell disease.”
Amy Simon, Chief Medical Officer of Beam Therapeutics
“At ASH, we look forward to sharing updated findings from a growing population of adolescent and adult patients from the trial, including, initial patient-reported outcomes data demonstrating improvements compared to baseline across measures of physical function, pain, fatigue and overall well-being.”
Amy Simon, Chief Medical Officer of Beam Therapeutics
“These findings reinforce our confidence in risto-cel as we prepare for an anticipated BLA submission as early as year-end 2026 and work toward bringing this potentially transformative treatment to patients.”
Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity
U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026
Get started
Create a free account to read the full story.